Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the safety and tolerability of ALN-APP in patients with Early-Onset Alzheimer Disease. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Early-onset Alzheimer Disease

Drugs mentioned

• ALN-APP

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Early-Onset Alzheimer Disease | Phase 1 | Status: RECRUITING